An existing collaborative project unites researchers at the University of Chicago (UChicago) and the University of Navarra (Spain) to advance cancer treatments using radio-immunotherapy. The effort builds on a groundbreaking in vivo CRISPR screen conducted by Dr. Ainhoa Arina and her collaborators to identify genetic targets that make tumors more sensitive to radiation and immunotherapy or, conversely, contribute to treatment resistance. Initial findings, funded through a National Institutes of Health (NIH) R21 grant, have revealed promising targets now being validated.
Dr. Arina at UChicago focuses on treatment-sensitizing genes, while Dr. Juan Dubrot at the University of Navarra investigates resistance mechanisms. This synergistic approach leverages the strengths of two globally recognized institutions for cancer care and research: UChicago and University of Navarra.
The current project aims to accelerate progress through annual in-person meetings in Pamplona to coordinate research, strengthen ties with international collaborators, and present findings at global conferences like ImmunoRad in Paris. By fostering cross-institutional collaboration, this initiative seeks to address the unmet need for radiosensitizers, ultimately improving outcomes for cancer patients worldwide.